Drugnews｜藥時事

Taiwan Anti-infectives companies and pipeline landscape (November 2026) | Drugnews

At least 9 Taiwanese biotech companies are active in Anti-infectives, with 11 assets in development or on the market. The most advanced is TaiMed Biologics (4147)’s TMB-355 (FDA approved; Multidrug-resistant HIV-1 in heavily treatment-experienced adults failing their regimen). Data as of 2026-11-01; updated as new information becomes available.

Assets in development or on the market
Approved
2
Phase 3
1
Phase 2
4
Phase 1
1
Preclinical / other
3

Taiwan pipelines

13 / 13

TaiMed Biologics (4147)4147TMB-355Not disclosedFDA approvedMultidrug-resistant HIV-1 in heavily treatment-experienced adults failing their regimenNot disclosed2026-07-062026-07-06
2026-07-06
TAIGEN (4157)4157TG-1000Not disclosedChina marketing authorization approvedUncomplicated influenza A and B in adults and adolescents aged 12 years and olderNot disclosedNo dated update2025-12-11
2025-12-11
TCM (4169)4169U101Not disclosedPhase 3; recruitingRecurrent Urinary Tract Infections in WomenNot disclosedNo dated update2026-10-02
TaiMed Biologics (4147)4147TMB-365／TMB-380Not disclosedPhase 2; active not recruitingHIV -1 InfectionNot disclosedNo dated update2026-08-06
Oneness Biotech (4743)4743SNS812Not disclosedPhase 2; completedMild to Moderate COVID-19Not disclosedNo dated update2024-09-19
Advagene (6709)6709AD17002Not disclosedPhase 1 / Phase 2; completedCOVID-19Not disclosedNo dated update2023-12-22
Ever Supreme (6712)6712UMSC01Allogeneic umbilical cord mesenchymal stem cellsPhase 1 / Phase 2; active not recruitingCOVID-19 InfectionNot disclosedNo dated update2026-09-23
TaiMed Biologics (4147)4147TMB-365Not disclosedPhase 1; completedHIV-1-infectionNot disclosedNo dated update2021-10-06
TaiMed Biologics (4147)4147TMB-607Not disclosedPhase 1; terminatedHuman Immunodeficiency VirusNot disclosedNo dated update2020-05-12
Senhwa Biosciences (6492)6492CX-4945Not disclosedPhase 2; terminatedCommunity-acquired Pneumonia; SARS-CoV-2 -Associated Pneumonia; Influenza With PneumoniaNot disclosed2026-03-272026-01-08
Formosa Pharmaceuticals (6838)6838APP13002Not disclosedPreclinicalInfectious eye diseases and related ocular surface disordersNot disclosedNo dated update2026-05-06
Intelligene (7832)7832IG-001siRNAPreclinical studies ongoingCOVID-19Not disclosedNo dated update2026-07-16
Intelligene (7832)7832IG-002siRNAPreclinical studies ongoingInfluenzaNot disclosedNo dated update2026-07-16

Recent events

  1. TG-1000: Phase 3 trial authorized Source
  2. Trogarzo received TFDA license collection notice (company disclosure) Source
  3. TMB-365/380 Phase 2b last participant enrolled (company disclosure) Source
  4. PBTC-led medulloblastoma Phase 1/2 study terminated after NCI sponsorship expired (company disclosure) Source
  5. TG-1000: China marketing authorization approved Source

Related Drugnews analysis

FAQ

Which Taiwanese companies are developing Anti-infectives?

Currently, 9 companies are included: TaiMed Biologics (4147), TAIGEN (4157), TCM (4169), Oneness Biotech (4743), Advagene (6709), Ever Supreme (6712), Senhwa Biosciences (6492), Formosa Pharmaceuticals (6838), Intelligene (7832). Their drugs, stages and indications are in the pipeline table above.

Which Taiwan-listed stocks are linked to Anti-infectives?

Taiwan-listed companies directly involved in Anti-infectives R&D, manufacturing or licensing include: TaiMed Biologics (4147), TAIGEN (4157), TCM (4169), Oneness Biotech (4743), Advagene (6709), Ever Supreme (6712), Senhwa Biosciences (6492), Formosa Pharmaceuticals (6838), Intelligene (7832). Compiled from public information; this is not investment advice.

Which Taiwanese Anti-infectives program is most advanced?

TaiMed Biologics (4147)’s TMB-355 is at FDA approved (Multidrug-resistant HIV-1 in heavily treatment-experienced adults failing their regimen).

What is the latest important development in Taiwan’s Anti-infectives sector?

The latest record is 2026-08-10: TAIGEN (4157) TG-1000: Phase 3 trial authorized.

Source
How often is this data updated?

Data as of 2026-11-01; updated when companies announce new developments or clinical progress. Every entry includes its original source and date.

Methodology · Partners